glycerin, propylene glycol, isopropyl alcohol, glycerol formal and tetraglycol, and mixtures thereof.

34. The use according to any one of claims 27 to 31, wherein:
- the hydrophobic drug is meloxicam;
- the cyclodextrin or cyclodextrin derivative is 2-hydroxypropyl-β-cyclodextrin; and
- the at least one co-solvent is selected from the group consisting of: ethanol, glycerin, propylene glycol, isopropyl alcohol, glycerol formal and tetraglycol, and mixtures thereof.

35. The use according to any one of claims 27 to 31, wherein:
- the hydrophobic drug is carprofen;
- the cyclodextrin or cyclodextrin derivative is 2-hydroxypropyl-β-cyclodextrin; and
- the at least one co-solvent is selected from the group consisting of: ethanol, glycerin, propylene glycol, isopropyl alcohol, glycerol formal and tetraglycol, and mixtures thereof.

36. The use according to any one of claims 27 to 35, wherein the buffer is present and is effective to stabilise the hydrophobic drug and provide a pH in the first composition in a range of from about 4.0 to about 9.0 and is selected from the group consisting of: phosphate based, acid-phosphate based and citrate based buffers.

37. The use according to any one of claims 27 to 36, wherein the pharmaceutical composition further comprises at least one hydrophilic drug.

38. Use of an injectable pharmaceutical composition complying with the European Pharmacopoeia 2011 Test for Efficacy of Antimicrobial Preservation, satisfying at least the B criteria for parenterals, and the United States Pharmacopeia 2011 Guidelines for Antimicrobial Effectiveness Testing for Category 1 (injectable) products comprising:

- water,
- one or more water soluble complexes, each comprising a cyclodextrin or a cyclodextrin derivative and a hydrophobic drug,
- at least one preservative selected from the group consisting of: m-cresol, chlorocresol, chlorobutanol, benzethonium chloride, benzalkonium chloride, boric acid, cetylpyridinium chloride, cetrimide, phenol, phenylethanol and phenoxyethanol, and mixtures thereof,
- at least one co-solvent and
- optionally a buffer effective to provide a pH in the composition in a range of from about 4.0 to about 9.0,

in the preparation of a medicament for the purpose of anaesthetising a human being.

39. The use according to claim 38, wherein the hydrophobic drug is selected from the group consisting of: alfaxalone, propofol, meloxicam and carprofen.

40. The use according to claim 38 or claim 39, wherein the cyclodextrin or cyclodextrin derivative is selected from the group consisting of: α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, methyl substituted cyclodextrins, ethyl substituted

cyclodextrins, hydroxyalkyl substituted cyclodextrins, 2-hydroxypropyl-β-cyclodextrin, alkyl ether cyclodextrins, branched cyclodextrins, cationic cyclodextrins, quaternary ammonium cyclodextrins, anionic cyclodextrins, amphoteric cyclodextrins and sulfoalkyl ether β-cyclodextrins, and a modified form thereof, and mixtures thereof.

41. The use according to any one of claims 38 to 40, wherein the at least one co-solvent is selected from the group consisting of: ethanol, glycerin, propylene glycol, isopropyl alcohol, glycerol formal and tetraglycol, and mixtures thereof.